Trials Sponsors Conditions Drugs Pricing

Conditions

Cannabis Use Disorder Healthy Schizophrenia and Other Psychotic Disorders

Outcome Measures

Primary Outcomes (1)

Synaptic density in psychiatric disorders using SV2A receptor PET Imaging with [11C]APP311
To compare synaptic vesicle protein 2A (SV2A) density in two groups of subjects with psychiatric disorders (namely 'schizophrenia and other psychotic disorders', and 'cannabis use disorder') to that in healthy controls using the PET radiotracer 11C-APP311
One test day (one time point).

Secondary Outcomes (1)

Correlation of Synaptic density with cognition and EEG
One test day (one time point).

Study Arms (3)

Schizophrenia and other psychotic disorders

For each \[11C\]APP311 PET scan, up to 20 mCi of \[11C\]APP311 will be administered by infusion pump, followed by up to 120 minutes of dynamic PET data acquisition.

Drug: [11C]APP311

Cannabis Use Disorder

For each \[11C\]APP311 PET scan, up to 20 mCi of \[11C\]APP311 will be administered by infusion pump, followed by up to 120 minutes of dynamic PET data acquisition.

Drug: [11C]APP311

Healthy Control

For each \[11C\]APP311 PET scan, up to 20 mCi of \[11C\]APP311 will be administered by infusion pump, followed by up to 120 minutes of dynamic PET data acquisition.

Drug: [11C]APP311

Interventions

[11C]APP311Drug

It has been shown that radiotracer \[11C\]APP311 (aka \[11C\]UCB-J) displays high specificity and selectivity for the synaptic vesicle protein SV2A. Since this protein is expressed ubiquitously in active synapses, this tracer has the potential to be a general purpose tool for quantitative imaging of synaptic density.

Cannabis Use DisorderHealthy ControlSchizophrenia and other psychotic disorders

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years - 85 Years

Sexall

Healthy VolunteersYes

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodProbability Sample

Study Population

Recruiting Subjects with Schizophrenia and other Psychotic disorders Cannabis Use Disorder Healthy controls

You may qualify if:

Willing and able to give voluntary written informed consent

Sponsors & Collaborators

National Institute on Drug Abuse (NIDA)
NIHcollaborator
Yale University
Otherlead

Study Sites (1)

Conneticut Mental Health Center

New Haven, Connecticut, 06519, United States

Biospecimen

Retention: SAMPLES WITH DNA

When specimens and information are stored, researchers are careful to try to protect your identity from discovery by others. Samples and information will receive a unique code. Other researchers will only receive coded samples and information, and will not be able to link the code to subjects. Strict security safeguards are in place to reduce the chance of misuse or unplanned release of information.

MeSH Terms

Conditions

Schizophrenia

Condition Hierarchy (Ancestors)

Schizophrenia Spectrum and Other Psychotic DisordersMental Disorders

Study Design

Study Type: observational
Observational Model: CASE CONTROL
Time Perspective: PROSPECTIVE
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: Professor of Psychiatry

Study Record Dates

First Submitted

June 19, 2019

First Posted

June 21, 2019

Study Start

December 1, 2017

Actual (reported)

Primary Completion

December 2026

Estimated

SV2 PET Imaging With [11C]APP311

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Study Arms (3)

Schizophrenia and other psychotic disorders

Cannabis Use Disorder

Healthy Control

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Biospecimen

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Study Arms (3)

Schizophrenia and other psychotic disorders

Cannabis Use Disorder

Healthy Control

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Biospecimen

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations